Effects of inhibitors of the arachidonic acid cascade on primary muscle culture from a Duchenne muscular dystrophy patient

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 77, Issue 3-4, 2007, Pages 217-223

  Gati I ^a   Danielsson, O ^a   Betmark, T ^a   Ernerudh, J ^a   Ollinger K ^a   Dizdar, N ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DESMIN; DYSTROPHIN; DYSTROPHIN 1; INDOMETACIN; LIPOXYGENASE; MYOSIN HEAVY CHAIN; NORDIHYDROGUAIARETIC ACID; PHOSPHOLIPASE A2; PREDNISOLONE; PROSTAGLANDIN SYNTHASE; PROTEIN BCL 2; UNCLASSIFIED DRUG; UTROPHIN;

ARTICLE; CASE REPORT; CELL CULTURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MEGADOSE; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; HUMAN TISSUE; MALE; MUSCLE FIBER CULTURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ARACHIDONIC ACID; CELL PROLIFERATION; CELLS, CULTURED; CHILD, PRESCHOOL; DESMIN; HUMANS; INDOMETHACIN; MALE; MUSCLE FIBERS; MUSCLES; MUSCULAR DYSTROPHY, DUCHENNE; NORDIHYDROGUAIARETIC ACID; OSMOLAR CONCENTRATION; PREDNISOLONE; UTROPHIN;

EID: 36349034720     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2007.10.002     Document Type: Article

References (46)

1. Whitehead N.P., Yeung E.W., and Allen D.G. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin. Exp. Pharmacol. Physiol. 33 (2006) 657-662
2. Folco C., and Murphy R.C. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58 (2006) 375-388
3. Bailey J.M. New mechanisms for effects of anti-inflammatory glucocorticoids. Biofactors 3 (1991) 97-102
4. Tanaka H., Watanabe K., Tamaru H., and Yoshida M. Arachidonic acid metabolites and glucocorticoid regulatory mechanism in cultured porcine tracheal smooth muscle cells. Lung 173 (1995) 347-361
5. Keeling R.M., Golumbek P.T., Streif E.M., and Connolly A.M. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 35 (2007) 43-48
6. DeSilva S., Drachman D.B., Mellits D., and Kuncl R.W. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch. Neurol. 44 (1987) 818-822
7. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41 (1991) 1874-1877
8. Barton-Davis E.R., Cordier L., Shoturma D.I., Leland S.E., and Sweeney H.L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104 (1999) 375-381
9. Howard M.T., Shirts B.H., Petros L.M., Flanigan K.M., Gesteland R.F., and Atkins J.F. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol. 48 (2000) 164-169
10. Grounds M.D., and Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J. 18 (2004) 676-682
11. Aurino S., and Nigro V. Readthrough strategies for stop codons in Duchenne muscular dystrophy. Acta Myol. 25 (2006) 5-12
12. Hodgetts S., Radley H., Davies M., and Grounds M.D. Reduced necrosis of dystrophis muscle by depletion of host neutrophils, or blocking TNFα function with Etanercept in mdx mice. Neuromuscul. Disord. 16 (2006) 591-602
13. Dorchies O.M., Wagner S., Vuadens O., et al. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am. J. Physiol. Cell Physiol. 290 (2006) C616-C625
14. Martinez-Salgado C., Rodriguez-Barbero A., Rodrigez-Puyol D., Perez de Lema G., and Lopez-Novoa J.M. Involvement of phospholipase A2 in gentamicin-induced rat mesangial cell activation. Am. J. Physiol. 273 (1997) F60-F66
15. Horiguchi J., Spriggs D., Imamura K., Stone R., Luebbers R., and Kufe D. Role of arachidonic acid metabolites in transcriptional induction of tumor necrosis factor gene expression by phorbol ester. Mol. Cell Biol. 9 (1989) 252-258
16. Mizugaki M., Ishizawa F., Yamazaki T., and Hishinuma T. Epigallocatechin gallate increase the prostacyclin production of bovine aortic endothelial cells. Prostaglandins Other Lipid Mediat. 62 (2000) 157-164
17. Llados F.T. Muscle damage induced by the ionophore A23187 can be prevented by prostaglandin inhibitors and leupeptin. Experientia 41 (1985) 1551-1552
18. McLennan L.S. Inhibition of prostaglandin synthesis produce a muscular dystrophy like myopathy. Exp. Neurol. 89 (1985) 616-621
19. Bentzer P., and Grande P.O. Low-dose prostacyclin restores an increased protein permeability. J. Trauma 56 (2004) 385-392
20. Ma X.Q., Fu R.F., Feng G.Q., Wang Z.J., Ma S.G., and Weng S.A. Hypoxia-reoxygenastion-induced apoptosis in cultured neonatal rat cardiomyocytes and the protective effect of prostaglandin. Clin. Exp. Phalrmacol. Physiol. 32 (2005) 1124-1130
21. LaPonte M.C., and Sitkins J.R. Phospholipase A2-metabolites regulate inducible nitric oxide synthase in myocytes. Hypertension 31 (1998) 218-224
22. 2+ elevation and contraction of the human detrusor muscle. J. Urol. 170 (2003) 638-644
23. Ito H., Ueda H., Iwamoto I., et al. Nordihydroguaiaretic acid (NDGA) block the differentiation of C2C12 myoblast cells. J. Cell Physiol. 202 (2005) 874-879
24. Basavappa S., Pedersen S.F., Jorgensen N.K., Ellory J.C., and Hoffmann E.K. Swelling-induced arachidonic acid release via the 85-kDa cPLA2 in human neuroblastoma cells. J. Neurophysiol. 79 (1998) 1441-1449
25. Lambert I.H., Pedersen S.F., and Poulsen K.A. Activation of PLA2 isoforms by cell swelling and ischaemia/hypoxia. Acta Physiol. (Oxf) 187 (2006) 75-85
26. Seiler G., Welle M., Busato A., Lin S., and Gaschen F.P. Mast cell proliferation and alterations in bFGF amount and localization are involved in the response of muscle to dystrophin deficiency in hypertrophic feline dystrophy. Neuromuscul. Disord. 11 (2001) 56-71
27. 2+ entry and Cl- channel activity. FEBS Lett. 554 (2003) 494-500
28. Menke A., and Jockush H. Extent of shock-induced membrane leakage in human and mouse myotubes depends on dystrophin. J. Cell Sci. 2 108/Part (1995) 727-733
29. Leijendekker W.J., Passaquin A.C., Metzinger L., and Ruegg U.T. Regulation of cytosolic calcium in skeletal muscle cells of the mdx mouse under conditions of stress. Br. J. Pharmacol. 118 (1996) 611-616
30. Guerriero Jr V., and Florini J.R. Dexamethasone effects on myoblast proliferation and differentiation. Endocrinology 106 (1980) 1198-1202
31. Passaquin A.C., Metzinger L., Leger J.J., Warter J.M., and Poindron P. Prenidolone endhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mouse. J. Neurosci. Res. 35 (1993) 363-372
32. te Pas M.F., de Jong P.R., and Verburg F.J. Glucocorticoid inhibition of C2C12 proliferation rate and differentiation capacity in relation to mRNA levels of the MRF gene family. Mol. Biol. Rep. 27 (2000) 87-98
33. Courdier-Fruh I., Barman L., Briguet A., and Meier T. Glucocorticoid-mediated regulation of utrophin levels in human muscle fibers. Neuromuscul. Disord. 12S (2002) 95-104
34. Ma K., Mallidis C., Bhasin S., et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. 285E (2003) 363-371
35. Fisher I., Abraham D., Bouri K., Hoffman E.P., Muntoni F., and Morgan J. Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J. 19 (2005) 834-857
36. Sklar R.M., and Brown Jr R.H. Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro. J. Neurol. Sci. 101 (1991) 73-81
37. Komamura K., Shirotani-Ikejima H., Tatsumi R., et al. Differential gene expression in the rat skeletal and heart muscle in glucocorticoid-induced myopathy: analysis by microarray. Cardiovasc. Drug Ther. 17 (2003) 303-310
38. Miyazawa K K., Iimori Y., Makino M., Mikami T., and Miyasaka K. Effects of some non-steroidal anti-inflammatory drugs and other agents on cyclooxygenase and lipoxygenase activities in some enzyme preparations. Jpn. J. Pharmacol. 38 (1985) 199-205
39. Culver C.A., Michalowski S.M., Maia R.C., and Laster S.M. The anti-apoptotic effects of nordihydroguaiaretic acid: inhibition of cPLA(2) activation during TNF-induced apoptosis arises from inhibition of calcium signalling. Life Sci. 77 (2005) 2457-2470
40. Tang D.G., Chen Y.Q., and Honn K.V. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Sci. USA 28 (1996) 5241-5246
41. Nishio E., and Watanabe Y. The regulation of mitogenesis and apoptosis in response to the persistent stimulation of alpha1-adrenoceptors: a possible role of 15-lipoxygenase. Br. J. Pharmacol. 122 (1997) 1516-1522
42. Biswal S.S., Datta K., Shaw S.D., Feng X., Robertson J.D., and Kehrer J.P. Glutathione oxidation and mitochondrial depolarization as mechanisms of nordihydroguaiaretic acid-induced apoptosis in lipoxygenase-deficient FL5.12 cells. Toxicol. Sci. 53 (2000) 77-83
43. Tong W.G., Ding X.Z., Witt R.C., and Adrian T.E. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol. Cancer Ther. 1 (2002) 929-935
44. Fujiwara T., Takami N., Misumi Y., and Ikehara Y. Nordihydroguaiaretic acid blocks protein transport in the secretory pathway causing redistribution of Golgi proteins into the endoplasmic reticulum. J. Biol. Chem. 273 (1998) 3068-3075
45. Ramoner R., Rieser C., Bartsch G., and Thurnher M. Nordihydroguaiaretic acid blocks secretory and endocytic pathways in human dendritic cells. J. Leukoc. Biol. 64 (1998) 747-752
46. Arasaki K., Tani K., Yoshimori T., Stephens D.J., and Tagaya M. Nordihydroguaiaretic acid affects multiple dynein-dynactin functions in interphase and mitotic cells. Mol. Pharmacol. 71 (2007) 454-460